Steve Lisi

CEO and Chairman of the Board

Steven Lisi has served on our Board since January 2017 and on the Board of Beyond Air Ltd., our wholly-owned subsidiary, since June 2016. Mr. Lisi was previously Senior Vice President of Business and Corporate Development at Avadel Pharmaceuticals (AVDL) where he was instrumental in restructuring the company, raising $121 million and transforming it from $100 million enterprise value to $1 billion in three years. Prior to his position at Avadel, Mr. Lisi spent 18 years investing in the global healthcare industry at SAC Capital, Millennium Management and Deerfield Management amongst others. He received his master’s degree in International Business from Pepperdine University.

Amir Avniel

President and Chief Operating Officer

Amir Avniel is the COO and co-founder of Beyond Air. He has over 20 years of experience leading biotechnology companies. Prior to Beyond Air, he co-founded Rosetta Green, which was eventually acquired by Monsanto. Prior to Rosetta Green, he served as the president and the Chief Executive Officer of Rosetta Genomics, a NASDAQ company. He studied computer science at the Academic College of Tel Aviv – Jaffa Israel and earned a bachelor’s degree in Social Sciences and Humanities from Open University in Israel. Prior to his academic studies, he served as an officer in the Israel Defense Force, where he was awarded four commendations for excellence.

Duncan Fatkin

Chief Commercial Officer

Duncan Fatkin joined Beyond Air as its Chief Commercial Officer in January 2019. Mr. Fatkin has a successful track record in the global medical device and biopharmaceutical industries, building out commercial capabilities, leading marketing and sales teams, and cultivating strong thought leader relationships across multiple specialties. His 30 years of experience includes, most recently, roles with Becton Dickinson (Worldwide Vice President, Injection, Diabetes Care), Zimmer Biomet (Vice President and General Manager, Office Based Technologies), Smith & Nephew/Bioventus (Vice President, Global Marketing & Reimbursement) and DePuy/Johnson & Johnson (Worldwide Vice President, iOrthopaedics). Mr. Fatkin has spent more than 10 years of his career in both Europe and the Asia Pacific region, with the last 9+ years in the United States. He received his bachelor of arts degree in Materials Science from Oxford University and his Diploma in Marketing from Thames Valley University.

Douglas Beck

Chief Financial Officer

Douglas Beck, CPA joined Beyond Air as its Chief Financial Officer in November 2018. Mr. Beck has been a Chief Financial Officer for five public companies, three of which were biotechnology companies. Mr. Beck has assisted companies’ raising equity and debt in excess of $100 million. He spent over four years at Lev Pharmaceutical, Inc. until the completion of a $618 million sale of the company. Mr. Beck serves on the New York State Society of CPAs Chief Financial Officer and SEC committee.

Frederick Montgomery, PhD

Vice President of Medical Systems

Fred Montgomery has spent the last 24 years developing and patenting NO delivery system technology leading to the commercialization of nitric oxide therapy. He led the development of the INOvent delivery system for Datex-Ohmeda, which in 1999 was the first FDA 510(k) cleared nitric oxide delivery system that led to the commercial marketing of INO Therapy in the year 2000. He established the Medical Device Group at INO Therapeutics which developed the INOmax DS and DSIR products, the leading NO delivery systems in the United States to this day. Mr. Montgomery left Ikaria (formerly INO Therapeutics) in 2011 and co-founded NitricGen Inc. He received his Doctor of Philosophy degree from the University of Salford, England and his Master’s of Business Administration from the University of Bradford, England.